Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04530981 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
A Phase 1 study of GIST - Gastrointestinal Stromal Tumor, sponsored by Deciphera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 3
- Study locations
NCT04530981 is a Phase 1 study of GIST - Gastrointestinal Stromal Tumor that has completed, run by Deciphera Pharmaceuticals. The registered enrollment target is 13 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT04530981, a Phase 1 study of GIST - Gastrointestinal Stromal Tumor, has completed, sponsored by Deciphera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 3
- Study locations
Study Summary
Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
Conditions Studied
Interventions
- DRUG Ripretinib
- DRUG Repaglinide
Study Locations (3)
Florida
- Mayo Clinic Florida - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2024-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04530981
The ClinicalTrials.gov registry entry for NCT04530981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with GIST - Gastrointestinal Stromal Tumor appearing as the primary indexed condition, and to 2 interventions - of which Ripretinib is the first listed.
NCT04530981 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT04530981 about?
NCT04530981 is a clinical study titled "A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST". Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate
What is the current status of trial NCT04530981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2021-09-22. Estimated completion is 2024-07-29.
What conditions does trial NCT04530981 study?
This clinical trial studies the following conditions: GIST - Gastrointestinal Stromal Tumor.
What interventions are being tested in trial NCT04530981?
The interventions under investigation include: Ripretinib (DRUG), Repaglinide (DRUG).
Who is sponsoring clinical trial NCT04530981?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04530981 being conducted?
This trial has 3 study locations across Florida, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.